Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects

Inclusion Criteria: * Male or female healthy subjects of any ethnic origin * Aged between 18 and 50 years of age * Body weight of ≥50 kg and body mass index (BMI) between 18.5 and 29 kg/m2 * FEV1 \> 90% of predicted * Able to demonstrate correct inhaler use * Written informed consent Exclusion Criteria: * History of clinically relevant allergies or idiosyncrasies to tobramycin or any other inactive ingredient(s) of the IMP * Any history of drug hypersensitivity, asthma, urticaria, or other significant allergic diathesis. * Any evidence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinological, metabolic, neurological, psychiatric or other diseases at screening * Surgery of the gastrointestinal or respiratory tract which might interfere with drug absorption * History of malignancy within the past 5 years * History of orthostatic hypotension, faintings or blackouts * Acute or chronic viral, bacterial or fungal airway infections, including laryngeal infections, mouth and throat infections, and hoarseness; * Other clinically relevant chronic or acute infectious illnesses * Clinical chemical, hematological or any other laboratory parameters clinically relevant outside the normal range